Immunic (NASDAQ:IMUX) Now Covered by Analysts at Chardan Capital

Chardan Capital initiated coverage on shares of Immunic (NASDAQ:IMUX) in a report released on Monday morning, AnalystRatings.com reports. The firm issued a buy rating and a $40.00 target price on the stock.

“We see this trial as potentially supportive of an accelerated path to approval/market for IMU-838, as PSC is an orphan indication, which may provide earlier revenues and/or help derisk testing of IMU-883 in larger market indications.”,” the firm’s analyst wrote.

Separately, ValuEngine upgraded shares of Immunic from a hold rating to a buy rating in a research report on Thursday, August 1st.

Immunic stock opened at $13.31 on Monday. Immunic has a fifty-two week low of $6.00 and a fifty-two week high of $372.00.

Immunic (NASDAQ:IMUX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.80). Equities analysts forecast that Immunic will post -3.05 earnings per share for the current year.

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. purchased a new stake in Immunic in the 2nd quarter valued at about $132,000. Tower Research Capital LLC TRC purchased a new stake in Immunic in the 2nd quarter valued at about $33,000. BlackRock Inc. purchased a new stake in Immunic in the 2nd quarter valued at about $145,000. Omega Fund Management LLC purchased a new stake in Immunic in the 2nd quarter valued at about $15,731,000. Finally, Independent Advisor Alliance purchased a new stake in Immunic in the 2nd quarter valued at about $804,000.

About Immunic

Immunic, Inc, a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies for treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its lead development program is IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH, which is in phase II clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis.

See Also: What are catch-up contributions?

Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.